Drug Trial Radar · NCT03729362
A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease
Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
125
Actual
Start
Dec 4, 2018
Primary completion
Dec 15, 2020
Study completion Jan 15, 2021
Sponsor
- Lead sponsor
- Amicus TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Nov 2, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 3 double-blind randomized study to study the efficacy and safety of intravenous ATB200 Co-administered with oral AT2221 in adult subjects with Late Onset Pompe Disease compared with Alglucosidase Alfa/placebo.
Conditions
- Pompe Disease (Late-onset)
Interventions
Cipaglucosidase AlfaBiological
Participants received an intravenous (IV) infusion dose over a 4-hour duration every 2 weeks (Q2W).
MiglustatDrug
Participants received weight-based doses 1 hour prior to cipaglucosidase alfa infusion Q2W.
Alglucosidase AlfaBiological
Participants received an IV infusion dose over a 4-hour duration Q2W.
PlaceboDrug
Miglustat matching placebo was administered orally 1 hour prior to alglucosidase alfa infusion Q2W.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 52 in 6 Minute Walk Distance (6MWD)Time frame: Baseline, Week 52
Locations
73 sites in 24 countries. Site status is shown where the registry gives one.
Neuromuscular Research Center
Phoenix, Arizona
University of Arkansas for Medical Sciences
Little Rock, Arkansas
University of California, Irvine
Irvine, California
UF Helath: University of Florida Clinical Research Center
Gainesville, Florida
University of South Florida Research Center
Tampa, Florida
Emory Clinic
Atlanta, Georgia
Indiana University Health Neuroscience Center
Indianapolis, Indiana
University of Kansas Medical Center
Kansas City, Kansas
University of Minnesota Clinical Research Unit
Minneapolis, Minnesota
Washington University School of Medicine
St Louis, Missouri
Billings Clinic
Billings, Montana
Hackensack University Medical Center
Hackensack, New Jersey
The Feinstein Institute for Medical Research
Manhasset, New York
NYU School of Medicine
New York, New York
Duke University Medical Center
Durham, North Carolina
University of Cincinnati Neurology
Cincinnati, Ohio
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
The Ohio State University Wexner Medical Center
Columbus, Ohio
Oregon Health & Science University
Portland, Oregon
Penn State Health Milton S. Hershey Medical Center
Hershey, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania
University of Texas Health Science Center San Antonio
San Antonio, Texas
University of Utah, Center for Clinical and Translational Sciences
Salt Lake City, Utah
Lysosomal and Rare Disorders Research
Fairfax, Virginia
Hospital Universitario Austral
Buenos Aires, Argentina
Westmead Hospital
Westmead, Australia
Royal Brisbane & Women's Hospital
Herston, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Monash Medical Centre
Melbourne, Victoria, Australia
Medizinische Universität Innsbruck
Innsbruck, Austria
UZ Leuven
Leuven, Belgium
University Clinical Centre of the Republic of Srpska
Banja Luka, Bosnia and Herzegovina
UMHAT Alexandrovska
Sofia, Bulgaria
Heritage Medical Research Clinic, University of Calgary
Calgary, Alberta, Canada
McMaster University Medical Centre
Hamilton, Ontario, Canada
Aarhus Universitets Hospital
Aarhus N, Denmark
Rigshospitalet Copenhagen Neuromuscular Center
Copenhagen, Denmark
Hôpital Neurologique Pierre Wertheimer
Bron, France
Hôpital Raymond Poincaré
Garches, France
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.